In its latest quarterly filing dated January 5, 2026, ALR Technologies SG Ltd. extended the expiry dates on 4.9 billion warrants held by senior insiders, signaling continued reliance on potential equity financing amid ongoing liquidity stress. The company, focused on innovative diabetes management systems for both humans and pets, reported negligible revenue generation with commercial activities only recently initiated. Despite FDA clearance and proprietary technology positioning in a niche veterinary market, ALR faces critical financial constraints with a severe working capital deficiency requiring urgent capital infusion to sustain operations. While strategic partnerships and product development continue—particularly around the GluCurve Pet CGM—execution risks and uncertain timeline for profitable scaling remain significant growth impediments.